Drug profile · INN
levoketoconazole
RECORLEV
levoketoconazole (RECORLEV) is a cytochrome p450 17a1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — levoketoconazole
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.84
Quick answer
levoketoconazole (RECORLEV) is a cytochrome p450 17a1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome P450 17A1 inhibitor
Primary target: Cholesterol side-chain cleavage enzyme, mitochondrial
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is levoketoconazole?
levoketoconazole (RECORLEV) is a cytochrome p450 17a1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for levoketoconazole?
RECORLEV is a marketed brand name for levoketoconazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levoketoconazole?
levoketoconazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.